CHMP recommends higher dose of Novo Nordisk's Ozempic

The EMA's expert committee, the CHMP, has reported a positive opinion of Novo Nordisk's application to extend the marketing its diabetes drug Ozempic to a new dose of 2.0 mg.


A new version of Novo Nordisk's once-weekly diabetes drug Ozempic looks to be on the road to European patients, the pharmaceutical company reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs